Sean J. Barbour

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

Fernando C. Fervenza, Gerald B. Appel, Sean J. Barbour et al. · New England Journal of Medicine · 2019 · 554 citations · Full text

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy

Sean J. Barbour, Rosanna Coppo, Hong Zhang et al. · JAMA Internal Medicine · 2019 · 442 citations · Full text

The MEST score provides earlier risk prediction in lgA nephropathy

Sean J. Barbour, Gabriela Espino-Hernández, Heather N. Reich et al. · Kidney International · 2015 · 279 citations · Full text

Mest Score, Glomerulonephritis, Medicine +7

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

David Z.I. Cherney, Claire C. J. Dekkers, Sean J. Barbour et al. · The Lancet Diabetes & Endocrinology · 2020 · 262 citations · Full text

Renal Function, Renal Disease, Crossover Trial +7

Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis

Sean J. Barbour, Allen Greenwald, Ognjenka Djurdjev et al. · Kidney International · 2011 · 206 citations

Glomerular Disease, Thrombosis, Hemodialysis +14